Atypical and Malignant Meningioma: Outcome and Prognostic Factors in 119 Irradiated Patients. A Multicenter, Retrospective Study of the Rare Cancer Network
| Autor: | Emine Canyilmaz, Brigitta G. Baumert, Nicolas Rezvoy, Salvador Villà, Ewa Szutowicz, Damien C. Weber, Deniz Yalman, Theo Veninga, René O. Mirimanoff, Marco Krengli, David Pasquier, Tzahala Tzuk-Shina, Stefan Bijmolt |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Malignant meningioma medicine.medical_treatment ddc:616.0757 Gastroenterology Meningioma Neoplasm Recurrence Local/mortality/radiotherapy Internal medicine Meningeal Neoplasms medicine Humans Radiology Nuclear Medicine and imaging External beam radiotherapy Prospective cohort study Survival rate Retrospective Studies Analysis of Variance Meningeal Neoplasms/mortality/*radiotherapy/surgery Univariate analysis Radiation business.industry Meningioma/mortality/*radiotherapy/surgery Retrospective cohort study Middle Aged medicine.disease Surgery Survival Rate Radiation therapy Treatment Outcome Oncology Female Neoplasm Recurrence Local business |
| Zdroj: | International Journal of Radiation Oncology, Biology, Physics, Vol. 71, No 5 (2008) pp. 1388-1393 |
| ISSN: | 0360-3016 |
| Popis: | PURPOSE: To retrospectively analyze and assess the outcomes and prognostic factors in a large number of patients with atypical and malignant meningiomas. METHODS AND MATERIALS: Ten academic medical centers participating in this Rare Cancer Network contributed 119 cases of patients with atypical or malignant meningiomas treated with external beam radiotherapy (EBRT) after surgery or for recurrence. Eligibility criteria were histologically proven atypical or anaplastic (malignant) meningioma (World Health Organization Grade 2 and 3) treated with fractionated EBRT after initial resection or for recurrence, and age >18 years. Sex ratio (male/female) was 1.3, and mean (+/-SD) age was 57.6 +/- 12 years. Surgery was macroscopically complete (Simpson Grades 1-3) in 71% of patients; histology was atypical and malignant in 69% and 31%, respectively. Mean dose of EBRT was 54.6 +/- 5.1 Gy (range, 40-66 Gy). Median follow-up was 4.1 years. RESULTS: The 5- and 10-year actuarial overall survival rates were 65% and 51%, respectively, and were significantly influenced by age >60 years (p = 0.005), Karnofsky performance status (KPS) (p = 0.01), and high mitotic rate (p = 0.047) on univariate analysis. On multivariate analysis age >60 years (p = 0.001) and high mitotic rate (p = 0.02) remained significant adverse prognostic factors. The 5- and 10-year disease-free survival rates were 58% and 48%, respectively, and were significantly influenced by KPS (p = 0.04) and high mitotic rate (p = 0.003) on univariate analysis. On multivariate analysis only high mitotic rate (p = 0.003) remained a significant prognostic factor. CONCLUSIONS: In this multicenter retrospective study, age, KPS, and mitotic rate influenced outcome. Multicenter prospective studies are necessary to clarify the management and prognostic factors of such a rare disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|